Pharmacokinetics of Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Tuberculosis
The Pharmacokinetics of Co-formulated Emtricitabine/Tenofovir/Efavirenz in HIV-infected Patients With Smear-positive Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania
Sponsor: African Poverty Related Infection Oriented Research Initiative
This PHASE2 trial investigates HIV Infections and Tuberculosis and is currently ongoing. African Poverty Related Infection Oriented Research Initiative leads this study, which shows 6 recorded versions since 2008 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Mar 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jan 2021 — Mar 2022 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Nov 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- African Poverty Related Infection Oriented Research Initiative
- Kilimanjaro Christian Medical Centre, Tanzania
- Radboud University Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .